You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

oxaliplatin

( ox-AL-ih-plah-tin )
Funding:
Evidence Building Program
  • Oxaliplatin (EBP) - Colorectal Cancer Patients with Resectable or Potentially Resectable Extrahepatic Metastases
  • Oxaliplatin (EBP) - Supplemental 1
  • Oxaliplatin (EBP) - Supplemental 2
New Drug Funding Program
  • Oxaliplatin and Irinotecan - Advanced Pancreatic Cancer (FOLFIRINOX)
  • Oxaliplatin - Adjuvant Colorectal Small Bowel or Appendiceal Cancer
  • Oxaliplatin - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
  • Oxaliplatin - With Surgery for Curative Intent for CRC SBAC Pts with Resectable or Potentially Resectable Liver Mets
  • Oxaliplatin - Second Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
Other Name(s): Eloxatin®
Appearance: clear, colourless solution mixed into larger bags of fluids

You might also be interested in